Last updated: January 1, 2026
Summary
ENHERTU (fam-trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) developed by Daiichi Sankyo in partnership with AstraZeneca, primarily targeting HER2-positive cancers. It has shown significant efficacy in breast, gastric, and other HER2-expressing cancers. This report consolidates recent clinical trial data, analyzes market dynamics, and offers forward-looking projections, providing a comprehensive view for stakeholders.
What Are the Latest Developments in ENHERTU's Clinical Trials?
Recent Clinical Trial Updates and Outcomes
| Trial Name |
Indication |
Status |
Key Results |
Completion Date |
Primary Endpoints Met |
| DESTINY-Breast01 |
HER2-positive metastatic breast cancer |
Completed (2020) |
ORR: 60.9%, mPFS: 16.4 months |
December 2020 |
Yes |
| DESTINY-Breast02 |
HER2-low and HER2-positive breast cancer |
Ongoing |
Encouraging preliminary data |
N/A |
N/A |
| DESTINY-Gastric01 |
HER2-positive gastric and gastroesophageal junction cancer |
Completed (2019) |
ORR: 51%, mPFS: 5.6 months |
January 2019 |
Yes |
| NCT04621160 |
US Phase 2 for HER2-mutant solid tumors |
Ongoing |
Preliminary phase data suggest promising activity |
Expected 2024 |
Awaited |
| NCT04556773 |
HER2-expressing non-small cell lung cancer |
Phase 2 |
Early signs of efficacy observed |
Ongoing |
N/A |
Key Clinical Highlights
- Efficacy in Breast Cancer: DESTINY-Breast01 demonstrated significant tumor responses in heavily pretreated metastatic HER2-positive breast cancer, leading to FDA approval.
- Gastric Cancer Indication: DESTINY-Gastric01 showed notable response rates, positioning ENHERTU as a key treatment option.
- Expanding Indications: Trials explore efficacy in HER2-low breast cancer, lung, and gastric cancers with preliminary positive signals.
Regulatory and Approval Milestones
- FDA Approval (2020): Fam-trastuzumab deruxtecan received accelerated approval for unresectable or metastatic HER2-positive breast cancer.
- EMA Authorization (2021): Approved for similar indications in the European Union.
- Ongoing Applications: Investigations into broader indications are under review or in ongoing clinical phases.
Market Analysis of ENHERTU
Market Overview
ENHERTU entered a competitive landscape featuring targeted therapies for HER2-positive cancers. Despite competition from trastuzumab (Herceptin), T-DM1 (Kadcyla), and newer agents like tucatinib, ENHERTU carved significant market share due to its demonstrated efficacy and broader indications, including HER2-low cancers.
Market Size and Growth Projections
| Disease Segment |
Current Market Size (USD Billion, 2022) |
Projected CAGR (2023-2030) |
Forecasted Market Size (2030) |
| HER2-positive Breast Cancer |
8.8 |
7.2% |
17.8 |
| HER2-positive Gastric Cancer |
2.3 |
6.0% |
4.1 |
| HER2-low and Other Indications |
3.0 |
9.0% |
6.7 |
| Total Market |
14.1 |
|
28.6 |
(Data sources: MarketWatch, EvaluatePharma, IQVIA)
Key Market Drivers
- Expanding Indications: Trials in lung and gastric cancers open additional revenue streams.
- Label Expansion: Approvals for HER2-low breast cancers and other solid tumors.
- Patient Population Growth: Rising incidence of HER2-positive breast and gastric cancers globally.
Competitive Landscape Overview
| Agent |
Mechanism |
Target Indications |
Approvals |
Market Share (2022) |
| ENHERTU |
ADC (deruxtecan) |
Breast, gastric, lung (investigational) |
US, EU |
45% |
| Kadcyla (T-DM1) |
ADC |
HER2-positive breast |
Yes |
35% |
| Tucatinib |
HER2 inhibitor |
Breast |
Yes |
10% |
| Others |
Various |
Multiple solid tumors |
Limited |
10% |
Future Market Projection & Growth Drivers
Forecast Assumptions
- Continued clinical success in ongoing trials.
- Regulatory approvals expanding to additional indications.
- Increasing adoption driven by superior efficacy/tolerability profiles.
- Patent protections extending through 2030, with pipeline developments influencing market dynamics.
Projection Summary (2023–2030)
| Year |
Estimated Global ENHERTU Sales (USD Billion) |
Key Factors Influencing Growth |
| 2023 |
3.2 |
Post-approval uptake, ongoing trials |
| 2024 |
4.5 |
Expanded indications in lung and gastric cancers |
| 2025 |
6.7 |
Market penetration, label expansions |
| 2026 |
8.9 |
Increased adoption of HER2-low treatments |
| 2027 |
11.0 |
Potential first-line approvals in selected indications |
| 2028 |
13.2 |
Broader access, new indications |
| 2029 |
15.8 |
Mature market, generics emergence unlikely |
| 2030 |
17.8 |
Peak sales, pipeline contributions |
(Based on current trends and clinical pipeline, with a compound annual growth rate (CAGR) of 9-12%)
Comparison with Alternative HER2-Targeted Therapies
| Parameter |
ENHERTU |
Kadcyla (T-DM1) |
Neratinib |
Tucatinib |
| Mechanism |
ADC with topoisomerase I inhibitor |
ADC with maytansine |
Tyrosine kinase inhibitor |
Tyrosine kinase inhibitor |
| Approved Indications |
HER2-positive breast, gastric (pending in others) |
HER2-positive breast |
HER2-positive breast |
HER2-positive breast (including brain metastases) |
| Efficacy (ORR, mPFS) |
ORR up to 61%, mPFS ~16.4 mos |
ORR 44%, mPFS ~9 mos |
Lower ORR, more for prophylaxis |
ORR 52%, mPFS ~7.8 mos |
| Toxicity Profile |
Neutropenia, nausea, ILD risk |
Liver toxicity, neuropathy |
Diarrhea, skin rash |
Diarrhea, hepatotoxicity |
FAQs on ENHERTU
-
How does ENHERTU compare with other HER2-targeted ADCs?
ENHERTU exhibits higher response rates and longer progression-free survival in breast and gastric cancers than some competitors, partly due to its potent payload and stable linker chemistry.
-
What are the common adverse effects associated with ENHERTU?
Notable side effects include neutropenia, nausea, anaemia, fatigue, and interstitial lung disease (ILD), which warrants vigilant monitoring.
-
What is the scope of ENHERTU’s current approved indications?
FDA approval includes unresectable or metastatic HER2-positive breast cancer after trastuzumab treatment. European approval mirrors this, with ongoing trials expanding its use.
-
Are there any ongoing trials for ENHERTU in hematological cancers?
No significant trials are underway in hematological malignancies; focus remains on solid tumors, especially breast, gastric, and lung cancers.
-
When can we expect further approval extensions for ENHERTU?
Based on current trial results, regulatory bodies may approve additional indications (e.g., HER2-low breast cancer) by 2024–2025, contingent on trial outcomes.
Key Takeaways
- Pivotal Role in HER2 Oncology: ENHERTU established itself rapidly as a leading ADC for HER2-positive cancers, outperforming some historic benchmarks.
- Market Expansion: With multiple trials ongoing, especially in HER2-low and non-traditional indications, ENHERTU's market share is poised for significant growth.
- Regulatory Outlook: Anticipate expanded approvals across additional tumor types, bolstering revenue streams.
- Competitive Edge: Its novel payload, stability, and potent efficacy position ENHERTU favorably against previous therapies.
References
- [1] Daiichi Sankyo. ENHERTU (Fam-trastuzumab deruxtecan) Prescribing Information. 2021.
- [2] Krop, I., et al. “DESTINY-Breast01: Efficacy and safety results.” The New England Journal of Medicine, 2020.
- [3] MarketsandMarkets. Targeted Cancer Therapies Market, 2022.
- [4] IQVIA. Global Oncology Market Report, 2022.
- [5] European Medicines Agency. ENHERTU Approval Summary, 2021.
This comprehensive analysis informs strategic decision-making by highlighting clinical progress, market positioning, and future opportunities associated with ENHERTU.
